JP2023500889A5 - - Google Patents

Info

Publication number
JP2023500889A5
JP2023500889A5 JP2022526005A JP2022526005A JP2023500889A5 JP 2023500889 A5 JP2023500889 A5 JP 2023500889A5 JP 2022526005 A JP2022526005 A JP 2022526005A JP 2022526005 A JP2022526005 A JP 2022526005A JP 2023500889 A5 JP2023500889 A5 JP 2023500889A5
Authority
JP
Japan
Prior art keywords
seq
composition according
approximately
ntki
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500889A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000969 external-priority patent/WO2021090069A1/en
Publication of JP2023500889A publication Critical patent/JP2023500889A/ja
Publication of JP2023500889A5 publication Critical patent/JP2023500889A5/ja
Pending legal-status Critical Current

Links

JP2022526005A 2019-11-07 2020-11-06 非チロシン標的化キナーゼ阻害剤との併用における成長因子抗体の使用のための方法及び組成物 Pending JP2023500889A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962932131P 2019-11-07 2019-11-07
US62/932,131 2019-11-07
US202063094018P 2020-10-20 2020-10-20
US63/094,018 2020-10-20
PCT/IB2020/000969 WO2021090069A1 (en) 2019-11-07 2020-11-06 Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2023500889A JP2023500889A (ja) 2023-01-11
JP2023500889A5 true JP2023500889A5 (https=) 2023-11-15

Family

ID=74106061

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526005A Pending JP2023500889A (ja) 2019-11-07 2020-11-06 非チロシン標的化キナーゼ阻害剤との併用における成長因子抗体の使用のための方法及び組成物

Country Status (11)

Country Link
US (1) US20220378891A1 (https=)
EP (1) EP4054619A1 (https=)
JP (1) JP2023500889A (https=)
KR (1) KR20220099990A (https=)
CN (1) CN115379851A (https=)
AU (1) AU2020378682A1 (https=)
BR (1) BR112022008704A2 (https=)
CA (1) CA3157334A1 (https=)
IL (1) IL292730A (https=)
MX (1) MX2022005306A (https=)
WO (1) WO2021090069A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
CN118984704A (zh) * 2022-02-18 2024-11-19 帕特恩电脑公司 治疗卵巢癌的药物组合和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
MX354902B (es) 2011-11-23 2018-03-23 Bioven 3 Ltd Proteínas recombinantes y sus usos terapéuticos.
CN107753954A (zh) * 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
EP2970409A2 (en) 2013-03-15 2016-01-20 Bioven 3 Limited Self-assembling synthetic proteins
JP2019522960A (ja) * 2016-04-21 2019-08-22 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗ｂｍｐｒ１ｂ抗体及び使用方法
AU2017368135A1 (en) * 2016-11-30 2019-06-13 Tyme, Inc. Tyrosine derivatives and compositions comprising them
KR20190112263A (ko) * 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
WO2018175251A1 (en) * 2017-03-20 2018-09-27 Celcuity Llc Methods of measuring signaling pathway activity for selection of therapeutic agents
JP7751357B2 (ja) * 2017-07-18 2025-10-08 イン３バイオ・リミテッド 合成タンパク質およびその治療学的用途
KR102811888B1 (ko) * 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법

Similar Documents

Publication Publication Date Title
CN103533961B (zh) 以表皮生长因子受体为靶向的治疗癌症的组合方法
RU2762746C2 (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
JP2023500889A5 (https=)
CN101998851A (zh) 吡铂和西妥昔单抗治疗结直肠癌的用途
JP2019517549A5 (https=)
GB2531094A (en) Anti-B7-H1 and Anti-CTLA-4 antibodies for treating non-small cell lung cancer
CA2792327A1 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
JP2007297398A (ja) 突然変異上皮成長因子受容体を標的とする試薬および方法
JP2016515619A (ja) カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
US20230070988A1 (en) Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer
WO2020239085A1 (zh) 治疗黑色素瘤的联用药物组合物
JP2024521696A5 (https=)
WO2022111618A1 (zh) 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物
CN119604291A (zh) Blu-945联合奥斯替尼治疗非小细胞肺癌
US20230321087A1 (en) Fgfr inhibitor combination therapies
JP2024516970A5 (https=)
WO2026019991A1 (en) Combinations comprising a kras g12c inhibitor, pembrolizumab and a steroid
WO2023111810A1 (en) Combination therapies and uses for treating cancer
EP4359003A1 (en) Erk1/2 and egfr inhibitors combination therapy
CN117858725A (zh) Erk1/2和egfr抑制剂组合疗法
HK40085445A (en) Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer
RU2021105387A (ru) Способы и композиции для подавления пути egf/egfr в комбинации с ингибиторами киназы анапластической лимфомы
JP2024540017A5 (https=)
CN117897158A (zh) Erk1/2和shp2抑制剂组合疗法